Table 2.
Treatment-related adverse events.
| AE | N° of patients (%)* | |||
|---|---|---|---|---|
| G1 | G2 | G3 | G4 | |
| Asthenia | 1 (11,1) | 0 | 0 | 0 |
| Fatigue | 1 (11,1) | 0 | 0 | 0 |
| Local reaction at vaccine | 3 (33,3) | 0 | 0 | 0 |
| Nausea# | 1 (11,1) | 1 (11,1) | 0 | 0 |
| Neutropenia# | 1 (11,1) | 0 | 0 | 1 (11,1) |
| Pain, specify | 1 (11,1) | 0 | 0 | 0 |
| Pruritus, spec if gen | 3 (33,3) | 1 (11,1) | 0 | 0 |
| Redness in site of injection | 1 (11,1) | 0 | 0 | 0 |
| Skin, specify | 1 (11,1) | 0 | 0 | 0 |
| Thrombocytopenia# | 0 | 0 | 1 (11,1) | 0 |
| Constipation | 1 (11,1) | 0 | 0 | 0 |
| Hypokalemia | 0 | 1 (11,1) | 0 | 0 |
#related to temozolomide
*Number of toxicity/percentage of toxicity calculated on 9 patients